1. Home
  2. KNSA vs WB Comparison

KNSA vs WB Comparison

Compare KNSA & WB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KNSA
  • WB
  • Stock Information
  • Founded
  • KNSA 2015
  • WB 2009
  • Country
  • KNSA United Kingdom
  • WB China
  • Employees
  • KNSA N/A
  • WB N/A
  • Industry
  • KNSA Biotechnology: Pharmaceutical Preparations
  • WB Computer Software: Programming Data Processing
  • Sector
  • KNSA Health Care
  • WB Technology
  • Exchange
  • KNSA Nasdaq
  • WB Nasdaq
  • Market Cap
  • KNSA 2.6B
  • WB 2.8B
  • IPO Year
  • KNSA 2018
  • WB 2014
  • Fundamental
  • Price
  • KNSA $38.36
  • WB $10.45
  • Analyst Decision
  • KNSA Strong Buy
  • WB Buy
  • Analyst Count
  • KNSA 7
  • WB 2
  • Target Price
  • KNSA $49.71
  • WB $14.00
  • AVG Volume (30 Days)
  • KNSA 546.2K
  • WB 941.1K
  • Earning Date
  • KNSA 10-28-2025
  • WB 11-18-2025
  • Dividend Yield
  • KNSA N/A
  • WB 15.71%
  • EPS Growth
  • KNSA N/A
  • WB 9.65
  • EPS
  • KNSA 0.47
  • WB 1.41
  • Revenue
  • KNSA $597,973,000.00
  • WB $1,762,960,000.00
  • Revenue This Year
  • KNSA $62.63
  • WB $0.82
  • Revenue Next Year
  • KNSA $29.93
  • WB $2.15
  • P/E Ratio
  • KNSA $82.19
  • WB $7.38
  • Revenue Growth
  • KNSA 55.68
  • WB 1.37
  • 52 Week Low
  • KNSA $17.82
  • WB $7.10
  • 52 Week High
  • KNSA $42.05
  • WB $12.96
  • Technical
  • Relative Strength Index (RSI)
  • KNSA 52.71
  • WB 31.25
  • Support Level
  • KNSA $36.56
  • WB $11.12
  • Resistance Level
  • KNSA $39.66
  • WB $10.85
  • Average True Range (ATR)
  • KNSA 1.58
  • WB 0.23
  • MACD
  • KNSA -0.13
  • WB -0.07
  • Stochastic Oscillator
  • KNSA 50.78
  • WB 10.30

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

About WB Weibo Corporation

Weibo Corp is a China-based company mainly engaged in the social media advertising business for people to create, discover and distribute content. The company's activities include Advertising and Marketing, which mainly provides a full range of advertising customization and marketing solutions. The Value-added Services mainly provide services such as membership services on social platforms, online games, live broadcasts, social e-commerce, and others. The Company's main product is the social platform Weibo.

Share on Social Networks: